Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix

International Journal of Radiation Oncology Biology Physics

Volumn 48, Issue 4, 2000, Pages 997-1006

  Santin, Alessandro D ^a,b,c   Hermonat, Paul L ^a   Ravaggi, Antonella ^a,b   Bellone, Stefania ^a,b   Roman, Juan ^a   Pecorelli, Sergio ^b   Cannon, Martin ^a   Parham, Groesbeck P ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Cervical cancer; Cisplatinum; Human papillomavirus; Immunosuppression; Radiotherapy

Indexed keywords

CD16 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CISPLATIN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; PERFORIN;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CELL COUNT; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE TRANSFORMATION; MULTIMODALITY CANCER THERAPY; NATURAL KILLER CELL; PRIORITY JOURNAL; RADIOTHERAPY; T LYMPHOCYTE; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNITY, CELLULAR; INTERFERON TYPE II; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PORE FORMING CYTOTOXIC PROTEINS; PROSPECTIVE STUDIES; RECEPTORS, INTERLEUKIN-2; UTERINE CERVICAL NEOPLASMS;

EID: 0034333028     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)00769-0     Document Type: Article

References (56)

1. Locally advanced cervical carcinoma; The role of chemo-radiation
2. A randomized trial of three cis-platinum dose schedules in squamous cell carcinoma of the uterine cervix
3. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation, and adjuvant hysterectomy for bulky stage IB cervical carcinoma
4. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high risk cervical cancer
5. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer
6. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes; A Gynecol Oncol Group and Southwest Oncology Group study
7. Intracellular surveillance of persisting viral infections; Human genital cancer results from deficient cellular control of papillomavirus gene expression
8. Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases
9. Rapidly progressing cervical cancer in a patient with human immunodeficiency virus infection
10. Viral warts, herpes simplex, and herpes zoster in patients with secondary immune deficiencies and neoplasms
11. Immunization against human papilloma virus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7
12. Human papilloma virus type 16 nucleoprotein Eqn. 7 is a tumor rejection antigen
13. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papilloma virus type 16
14. Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope
15. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes
16. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III
17. Induction of human papillomavirus-specific CD4+ and CD8+ lymphocytes by E7 pulsed autologous dendritic cells in patients with HPV16 and 18 positive cervical cancer
18. Lymphopenia and change in distribution of human B and T lymphocytes in peripheral blood induced by irradiation for mammary carcinoma
19. Long term changes in natural killer cytotoxicity after external pelvic radiotherapy
20. T cell subsets in patients treated with pelvic irradiation for cancer
21. Effect of chemotherapeutic agents on natural cell-mediated cytotoxicity in mice
22. Effects of chemotherapeutic agents on the immune response. II
23. Immune function in malignant cervical neoplasia; A multiparameter analysis
24. Development of an immunological staging system to prognosticate disease course in malignant cervical neoplasia
25. Lymphocyte subset analysis by flow cytometry. Comparison of three different staining techniques and effects of blood storage
26. Direct demonstration of cytokine synthesis heterogeneicity among human memory/effector T cells by flow cytometry
27. Natural killer cells and cancer
28. Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes
29. Behaviour of mild cervical dysplasia during long term follow-up
30. Association between poor prognosis in early-stage invasive cervical carcinoma and non-detection of HPV DNA
31. Increased age and mortality associated with cervical carcinomas negative for human papillomavirus RNA
32. The effect of treatment duration in the local control of cervix cancer
33. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation; A patterns-of-care study
34. Radiation-enhanced expression of E6/E7 transforming oncogenes of human papillomavirus 16 in human cervical cancer
35. Detection of human papillomavirus mRNA and cervical cancer cells in the peripheral blood of cervical cancer patients with metastasis
36. Detection of human papillomavirus type 16 and 18 mRNA in peripheral blood of advanced cervical cancer patients and its association with prognosis
37. Improved treatment for cervical cancer-Concurrent chemotherapy and radiotherapy
38. Neoadjuvant chemotherapy for cervical carcinoma
39. Concurrent chemoradiation in advanced cervical cancer
40. Randomized trial with neoadjuvant chemotherapy in stage IIIB squamous carcinoma cervix uteri; An unexpected therapeutic management
41. Neoadjuvant chemotherapy in cervical carcinoma stage IIB; a randomized controlled trial
42. Chemotherapeutic agents and modulation in natural killer cell activity in vitro
43. NK-cell activity affected by some cytostatic drugs and their additives
44. The enhancement of naturally occuring spontaneous monocyte-mediated cytotoxicity by cis-diamine-dichloroplatinum (II)
45. The effects of radiotherapy on immunity in patients with localized carcinoma of the cervix uteri
46. Lymphocyte subset distribution after radiation therapy for cancer of the uterine cervix. Possible prognostic implications and correlation with disease course
47. Interleukin-2 and alpha interferon induced in vitro modulation of spontaneous cell mediated cytotoxicity in patients with cancer of the uterine cervix undergoing radiotherapy
48. Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin-2 and local tumor irradiation
49. Activated (HLA-DR+) T lymphocytes subsets in cervical carcinoma and effects of radiotherapy and immunotherapy with sizofiran on cell-mediated immunity and survival
50. Effects of irradiation on the expression of major histocompatibility complex class I antigen and adhesion/costimulation molecules ICAM-1 in human cervical cancer
51. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity
52. Tumor microenviroment can restrict the effectiveness of activated antitumor lymphocytes